Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas
- 3 September 2015
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 37 (2) , 1959-1966
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- RE: CA 19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Preoperative TherapyAnnals of Surgical Oncology, 2013
- CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative TherapyAnnals of Surgical Oncology, 2012
- Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancerWorld Journal of Surgical Oncology, 2012
- The prognostic and predictive value of serum CA19.9 in pancreatic cancerAnnals of Oncology, 2012
- Prognostic factors for resectable pancreatic adenocarcinomaJournal of Visceral Surgery, 2011
- Failure of Normalization of CA19-9 Following Resection for Pancreatic Cancer is Tantamount to Metastatic DiseaseAnnals of Surgical Oncology, 2010
- Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status reportAnnals of Oncology, 2009
- Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704Journal of Clinical Oncology, 2008
- Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2007
- Prognostic Value of Serum CA 19–9 Levels in Pancreatic AdenocarcinomaAnnals of Surgery, 1992